Gain Therapeutics (GANX) Other Non Operating Income (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Other Non Operating Income of -$165173.0 for Q1 2026, down 64.21% year-over-year from -$461515.4 in Q1 2025, and down 110.35% quarter-over-quarter from $1.6 million in Q4 2025.
Gain Therapeutics (GANX) Other Non Operating Income (2020 - 2026) Analysis & Trends
Gain Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at -$165173.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 64.21% year-over-year to -$165173.0; the TTM figure through Mar 2026 stood at $782617.0 (up 413.62% YoY), while the FY2025 annual figure was $847204.0, up 611.22% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$165173.0, down from $1.6 million in the prior quarter.
- The five-year high for Other Non Operating Income was $1.6 million in Q4 2025, with the low at -$620924.0 in Q2 2025.
- The 5-year median for Other Non Operating Income is -$42842.0 (2023), against an average of $16219.5.
- Peak annual rise in Other Non Operating Income reached 10028.8% in 2025, while the deepest fall reached 1324.92% in 2025.
- Gain Therapeutics' Other Non Operating Income stood at -$198939.0 in 2022, then sank by 105.34% to -$408507.0 in 2023, then jumped by 103.86% to $15758.0 in 2024, then jumped by 10028.8% to $1.6 million in 2025, then sank by 110.35% to -$165173.0 in 2026.
- Business Quant data shows GANX's Other Non Operating Income at -$165173.0 in Q1 2026, $1.6 million in Q4 2025, and -$27382.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Gain Therapeutics | 85.97 Mn | 85.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 49,089.00 |
| Mar 31, 2026 | -165,173.00 |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | -27,382.00 |
| Jun 30, 2025 | -620,924.00 |
| Mar 31, 2025 | -100,586.00 |
| Dec 31, 2024 | 15,758.00 |
| Sep 30, 2024 | -121,139.00 |
| Jun 30, 2024 | -43,576.00 |
| Mar 31, 2024 | 268,077.00 |
| Dec 31, 2023 | -408,507.00 |
| Sep 30, 2023 | 82,198.00 |
| Jun 30, 2023 | -60,195.00 |
| Mar 31, 2023 | -42,842.00 |
| Dec 31, 2022 | -198,939.00 |
| Sep 30, 2022 | 43,491.00 |
| Jun 30, 2022 | 40,212.00 |
| Mar 31, 2022 | 19,162.00 |
| Dec 31, 2021 | -19,675.00 |
| Sep 30, 2021 | -27,412.00 |